Securities code: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) securities abbreviation: Sichuan Huiyu Pharmaceutical Co.Ltd(688553) Announcement No.: 2022018
Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
Special report on the deposit and actual use of raised funds in 2021
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall be responsible for the authenticity, accuracy and completeness of its contents
In accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the application of self regulatory rules for companies listed on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation and relevant business rules, the deposit and actual use of raised funds in Sichuan Huiyu Pharmaceutical Co.Ltd(688553) 2021 are as follows:
1、 Basic information of raised funds
(I) actual amount of raised funds and time of fund arrival
Approved by the reply on Approving the registration of initial public offering of Sichuan Huizi Pharmaceutical Co., Ltd. (zjxk [2021] No. 2596) issued by China Securities Regulatory Commission and approved by Shanghai Stock Exchange, the company publicly issued 63 Shanghai Pudong Development Bank Co.Ltd(600000) RMB ordinary shares (A shares) to the public by the lead underwriter China Securities Co.Ltd(601066) using the method of balance underwriting, with an issue price of 38.87 yuan per share, The total raised capital is 247213200000 yuan, and the raised capital after deducting 9887476377 yuan of underwriting and recommendation fees (excluding value-added tax) is 237325723623 yuan, which has been remitted by the lead underwriter China Securities Co.Ltd(601066) on October 18, 2021 to the special account for raised capital with the account number of 020000437622 opened by the company in Neijiang branch of Leshan Commercial Bank Co., Ltd. In addition, after deducting 1258239177 yuan of new external expenses (excluding value-added tax) directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, reporting accountant fee and lawyer fee, the net amount of funds raised by the company this time is 236067484446 yuan. The availability of the above raised funds has been verified by Tianjian Certified Public Accountants (special general partnership), who will issue the capital verification report (tianjianyan [2021] No. 11-44).
(II) amount used in the current year and ending balance
As of December 31, 2021, the balance of the raised funds account is as follows:
Monetary unit: RMB 10000
Item No. amount
Net amount of raised funds a 23606748
Project input B1
Accumulated amount as of the beginning of the period permanent replenishment of working capital B2
Net interest income B3
Project input C11589438
Amount incurred in the current period: permanent supplementary working capital C23279862
Net interest income [note] C3 440.16
Project investment D1 = B1 + C11589438
Accumulated amount as of the end of the period: permanent supplementary working capital D2 = B2 + C23279862
Net interest income [note] D3 = B3 + C3 440.16
The balance of funds raised should be e = a-d1-d2 + D318781464
Actual balance of raised funds f 18781464
Difference g = E-F 0.00
[note] net interest income refers to the net amount of interest received from bank deposits minus bank charges.
2、 Management of raised funds
(I) management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of the Kechuang board of Shanghai Stock Exchange (revised in December 2020) (SZF [2020] No. 101) and the self discipline supervision guidelines for companies listed on the Kechuang board of Shanghai Stock Exchange No. 1 – standardized operation (SZF [2022] No. 14) and other relevant laws, regulations and normative documents, and in combination with the actual situation of the company, The administrative measures for Sichuan Huiyu Pharmaceutical Co.Ltd(688553) raised funds (hereinafter referred to as the administrative measures) has been formulated. In accordance with the administrative measures, the company implements a special account for the raised funds, establishes a special account for the raised funds in the bank, and together with the sponsor China Securities Co.Ltd(601066) on October 15, 2021, respectively, with Bank Of China Limited(601988) Neijiang branch, the business office of Neijiang branch of Leshan Commercial Bank Co., Ltd., Neijiang branch of Bank of Sichuan Co., Ltd
China Merchants Bank Co.Ltd(600036) Chengdu Wuhou sub branch, China Citic Bank Corporation Limited(601998) Chengdu Tianfu sub branch and Shanghai Pudong Development Bank Co.Ltd(600000) Huafu Avenue sub branch signed the tripartite supervision agreement on raised funds respectively, clarifying the rights and obligations of all parties. There is no significant difference between the tripartite regulatory agreement and the model tripartite regulatory agreement of Shanghai Stock Exchange, and the company has strictly complied with the raised funds.
(II) storage of raised funds in special account
As of December 31, 2021, the company has 6 special accounts for raising funds, 1 time deposit account and 8 structured deposit accounts.
The deposit of raised funds is as follows:
Unit: Yuan
Remarks on the balance of raised funds in the account number of the deposit bank
Leshan Commercial Bank Co., Ltd. Neijiang branch 02000043762252856154913
Leshan Commercial Bank Co., Ltd. Neijiang branch 0200045687930000000000 time deposit
Bank Of China Limited(601988) Neijiang branch 122623086014278 Mayinglong Pharmaceutical Group Co.Ltd(600993) 2
Bank Of China Limited(601988) Neijiang branch 11587014860600102 6499000000 structured deposit
Bank Of China Limited(601988) Neijiang branch 11587014860 Fujian Qingshan Paper Industry Co.Ltd(600103) 6501000000 structured deposit
Bank Of China Limited(601988) Neijiang branch 11587014860 Chongqing Road & Bridge Co.Ltd(600106) 17501000000 structured deposit
Bank Of China Limited(601988) Neijiang branch 11587014860 Hubei Mailyard Share Co.Ltd(600107) 17499000000 structured deposit
Bank Of China Limited(601988) Neijiang branch 11587014860 Gansu Yasheng Industrial (Group) Co.Ltd(600108) 2000000000 structured deposit
China Citic Bank Corporation Limited(601998) Chengdu Tianfu sub branch 811100101 Nations Technologies Inc(300077) 11571670222501
China Citic Bank Corporation Limited(601998) Chengdu Tianfu sub branch 811100111190079542414500000000 structured deposit
China Citic Bank Corporation Limited(601998) Chengdu Tianfu sub branch 8111001113700787750 Shanghai Pudong Development Bank Co.Ltd(600000) 0000 structured deposit
Shanghai Pudong Development Bank Co.Ltd(600000) Washington Avenue branch 731500788016 Shenzhen Guohua Network Security Technology Co.Ltd(000004) 7015234.41
that ‘s ok
Shanghai Pudong Development Bank Co.Ltd(600000) Washington Avenue Branch [note] 20000000000 structured deposit bank
China Merchants Bank Co.Ltd(600036) Chengdu Wuhou sub branch 1289059140101186666.67
China Merchants Bank Co.Ltd(600036) Chengdu Wuhou sub branch 1289059140810001710000000000 structured deposit
Neijiang branch of Bank of Sichuan Co., Ltd. 792201 Tangshan Jidong Cement Co.Ltd(000401) 04647666.01
Total 187814644055
[note] Shanghai Pudong Development Bank Co.Ltd(600000) Huafu Avenue sub branch has no separate bank account for structural deposit
3、 Actual use of raised funds this year
(I) use of funds for investment projects with raised funds
As of December 31, 2021, the actual use of the company’s raised funds is detailed in “Annex 1: comparison table of the use of raised funds”.
(II) description of abnormal conditions in the project invested by raised funds
There are no abnormalities in the investment projects of the company with raised funds.
(III) description of the situation that the benefits of the investment project with raised funds cannot be calculated separately
1. “Huiyu innovative drug research institute construction project” can greatly improve the software and hardware strength of the company’s R & D, accelerate the progress of the company’s product R & D, and enhance the company’s future competitiveness. It is impossible to calculate the benefits separately.
2. The supplementary working capital project is mainly to help the company to continuously improve its economic benefits and healthy and sustainable development, enhance the company’s capital strength and meet the capital needs of the company’s operation. It is impossible to calculate the benefits separately.
4、 Change the use of funds of raised investment projects
In 2021, the company did not change the investment projects of raised funds.
5、 Problems in the use and disclosure of raised funds
This year, there were no major problems in the use and disclosure of the raised funds of the company.
6、 Concluding opinions of the assurance report issued by the accounting firm on the deposit and use of the company’s annual raised funds
Tianjian Certified Public Accountants (special general partnership) believes that the 2021 special report on the annual deposit and use of raised funds prepared by the board of directors of Sichuan Huiyu Pharmaceutical Co.Ltd(688553) company complies with the provisions of self regulatory guidelines No. 1 – standardized operation of companies listed on the science and Innovation Board of Shanghai Stock Exchange (SZF [2022] No. 14) and relevant format guidelines, It truthfully reflects the actual deposit and use of the funds raised by Sichuan Huiyu Pharmaceutical Co.Ltd(688553) company in 2021.
After verification, The sponsor believes that the deposit and use of the company’s raised funds in 2021 comply with the measures for the administration of securities issuance and listing recommendation business, the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the application of self regulatory rules for listed companies on the science and Innovation Board of Shanghai Stock Exchange No. 1 – standardized operation, and the Listing Rules of shares on the science and Innovation Board of Shanghai Stock Exchange In accordance with the requirements of relevant laws, regulations and regulations such as the measures for the continuous supervision of listed companies on the science and Innovation Board (for Trial Implementation), the raised funds have been deposited and used in a special account. There is no case of changing the purpose of the raised funds in a disguised manner and damaging the interests of shareholders, and there is no case of illegal use of the raised funds.
Annex 1: comparison table of use of raised funds
It is hereby announced
Sichuan Huiyu Pharmaceutical Co.Ltd(688553)
